View : 839 Download: 232

Full metadata record

DC Field Value Language
dc.contributor.author유재두*
dc.date.accessioned2017-07-04T01:07:36Z-
dc.date.available2017-07-04T01:07:36Z-
dc.date.issued2017*
dc.identifier.issn1471-2474*
dc.identifier.otherOAK-20756*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/235419-
dc.description.abstractBackground: This randomized, double-blind, multi-center, non-inferiority trial was conducted to assess the efficacy and safety of a cross-linked hyaluronate (XLHA, single injection form) compared with a linear high molecular hyaluronate (HMWHA, thrice injection form) in patients with symptomatic knee osteoarthritis. Methods: Two hundred eighty seven patients with osteoarthritis (Kellgren-Lawrence grade I to III) were randomized to each group. Three weekly injections were given in both groups but two times of saline injections preceded XLHA injection to maintain double-blindness. Primary endpoint was the change of weight-bearing pain (WBP) at 12 weeks after the last injection. Secondary endpoints included Western Ontario and McMaster Universities Osteoarthritis index; patient's and investigator's global assessment; pain at rest, at night, or in motion; OMERACT-OARSI responder rate; proportion of patients achieving at least 20 mm or 40% decrease in WBP; and rate of rescue medicine use and its total consumption. Results: Mean changes of WBP at 12 weeks after the last injection were -33.3 mm with XLHA and -29.2 mm with HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (-1.9 mm, 10.1 mm) was well above the predefined margin (-10 mm). There were no significant between-group differences in all secondary endpoints. Injection site pain was the most common adverse event and no remarkable safety issue was identified. Conclusions: This study demonstrated that a single injection of XLHA was non-inferior to three weekly injections of HMWHA in terms of WBP reduction, and supports XLHA as an effective and safe treatment for knee osteoarthritis. Trial registration: ClinicalTrials.gov (NCT01510535). This trial was registered on January 6, 2012. © 2017 The Author(s).*
dc.languageEnglish*
dc.publisherBioMed Central Ltd.*
dc.subjectHyaluronic acid*
dc.subjectInflammation*
dc.subjectKnee osteoarthritis*
dc.subjectTreatment*
dc.titleEfficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: A double-blind, randomized, multi-center, non-inferiority study*
dc.typeArticle*
dc.relation.issue1*
dc.relation.volume18*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.journaltitleBMC Musculoskeletal Disorders*
dc.identifier.doi10.1186/s12891-017-1591-4*
dc.identifier.wosidWOS:000402333300003*
dc.identifier.scopusid2-s2.0-85019654628*
dc.author.googleHa C.-W.*
dc.author.googlePark Y.-B.*
dc.author.googleChoi C.-H.*
dc.author.googleKyung H.-S.*
dc.author.googleLee J.-H.*
dc.author.googleYoo J.D.*
dc.author.googleYoo J.-H.*
dc.author.googleKim C.-W.*
dc.author.googleKim H.-C.*
dc.author.googleOh K.-J.*
dc.author.googleBin S.-I.*
dc.author.googleLee M.C.*
dc.contributor.scopusid유재두(16641404300)*
dc.date.modifydate20240118131633*


qrcode

BROWSE